News Quantified

PLRX – pliant therapeutics, inc. (US:NASDAQ)

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

12/1

08:30 am

plrx

Low

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Pliant Therapeutics (NASDAQ:PLRX) was upgraded by analysts at Wall Stree

Pliant Therapeutics (NASDAQ:PLRX) had its price target lowered by analysts at Royal Bank Of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}